33 results about "Anti proteases" patented technology

The present application provides protease-resistant Glucagon-Like Peptide 1 (eGLP-1) peptides, and also provides protease-resistant dual agonist peptides against GLP-1R and GIPR, methods of making such peptides, as well as compositions comprising protease-resistant peptides and methods of treatment utilizing such peptides.

The invention provides a cyclic peptide as well as a preparation method and application thereof. The cyclic peptide has an amino acid sequence # imgabs0 # represented by formula (1) (wherein X is a Lys residue modified with a fatty acid molecule, and a line connecting Arg and Lys represents an amide bond. The cyclic peptide prepared by the invention has wide antifungal activity and antibacterial activity on drug-resistant bacteria; meanwhile, the biotoxicity and the protease degradation resistance are high, and the in-vivo antibacterial effect of the cyclopeptide can be prolonged. The cyclic peptide can be applied to preparation of anti-bacterial and anti-fungal infection drugs, and can be used as an excellent substitute drug or an auxiliary drug of existing antibiotics. The method for preparing the cyclic peptide is simple, raw materials are easy to obtain, and industrial production can be achieved.

The invention discloses a BimBH3 analogue containing D-type amino acid and N-terminal fatty acid acylation, a preparation method of the BimBH3 analogue and application of the BimBH3 analogue as a PTPN1 inhibitor to development of hypoglycemic drugs. The structural general formula of the novel BimBH3 mimic peptide analogue is shown as a formula I: # imgabs0 #, wherein Raa2 is equal to D-His, D-Leu, D-Pro, D-Ser, D-Arg, D-Gln, D-Lys, D-Trp, D-Val, D-Tyr, D-Ala, Raa3 is equal to D-Gln, Raa7 is equal to D-Arg, and Raa8 is equal to D-Allo-Ile. The mimic peptide compound is derived from a core region of a Bim-BH3 structural domain, different D-type amino acid site-specific replacement modification and N-terminal conjugated hexadecanoic acid modification are adopted for amino acids at the second, third, seventh and eighth sites respectively, the BimBH3 mimic peptide modified by the D-type amino acid is more stable and has higher metabolic stability, and the target binding capacity and inhibitory activity of the BimBH3 mimic peptide can still be reserved or even improved. The BimBH3 mimic peptide compound shows an excellent PTPN1 inhibitor, the ability of resisting protease hydrolase and various digestive enzymes is also remarkably improved, and the BimBH3 mimic peptide compound has longer pharmacological action time and can play a potential long-acting hypoglycemic role through subcutaneous injection or oral administration. The compound is completely prepared by a polypeptide solid-phase synthesis method, and an obtained crude product is subjected to semi-preparative liquid chromatography purification and freeze-drying to obtain a target compound.

The invention relates to an anti-hair loss and hair growth peptide with alternately arranged D / L amino acids as well as a preparation method and application of the anti-hair loss and hair growth peptide, and belongs to the technical field of biological medicines. The amino acid sequence of the polypeptide is shown as SEQ ID NO: 1, D-type and L-type amino acids are alternately arranged and designed, the protease degradation resistance is remarkably enhanced, the in-vitro half-life period is larger than or equal to 48 hours, and beta-catenin protein expression in hair follicle stem cells is activated. The preparation method comprises the following steps: taking Rink Amide resin as a carrier, sequentially coupling D / L type amino acid by adopting an Fmoc solid-phase synthesis method, cracking the resin by trifluoroacetic acid, and purifying by high performance liquid chromatography, so that the yield is more than or equal to 80%, the purity is more than or equal to 96%, and the molecular weight is confirmed to be 956.12 Da by mass spectrometry. The polypeptide can be applied to preparation of anti-hair loss and hair growth cosmetics, medicines and medical instruments, and effectively solves the problems of low stability and insufficient targeting of the polypeptide in the prior art. # imgabs0 #

The invention discloses an antibacterial skin-care cleansing lotion and a preparation method thereof, and belongs to the technical field of personal care products. The skin cleansing liquid comprises the following core components: a double-embedded tea tree oil microcapsule, wherein the inner layer of the double-embedded tea tree oil microcapsule comprises beta-cyclodextrin inclusion tea tree oil, the outer layer of the double-embedded tea tree oil microcapsule comprises a sodium alginate-chitosan ionic cross-linked membrane, natural antibacterial peptide PA-3, dipotassium glycyrrhizinate, sodium lauroyl sarcosinate, a hyaluronic acid cross-linked polymer and a pH buffer system. The preparation method comprises the following steps: constructing a dual-embedding microcapsule through spray drying-ionic crosslinking to realize slow release of the tea tree oil; the hyaluronic acid three-dimensional network is used for loading PA-3, and protease degradation is resisted; and uniform dispersion of the microcapsules is ensured by adopting biaxial shearing emulsification. The product has the advantages of efficient antibiosis, gradient controlled release, low irritation and thermal stability, and is suitable for daily skin care and cleaning and repairing of sensitive and damaged skin.

The present invention relates to the technical field of genetic engineering. Particularly provided are an identification marker for early chronic obstructive pulmonary disease and the use thereof in a diagnostic kit. The identification marker for the early chronic obstructive pulmonary disease is screened, which is miRNA1255a in serum-derived exosomes; in addition, biological function analysis after sequencing proves that among a plurality of target genes of miRNA1255a, the tissue inhibitor of metalloprotease (TIMP-2) and CD36, which are genes related to the protease / antiprotease balance, are involved in the Ca ion signaling pathway, and moreover, the expression of CD36 and TIMP-2 proteins proves that said two proteins are negatively correlated with miRNA1255a. Moreover, it is found in detection results that the expression of TIMP-2 and the expression of CD36 are all downregulated when the expression of miRNA1255a is upregulated. The biomarker for the early chronic obstructive pulmonary disease is provided, which can easily screen potential patients with early onset of chronic obstructive pulmonary disease.

The invention discloses a cationic peptide compound for targeting cartilage as well as a preparation method and application of the cationic peptide compound. The cationic peptide compound has a structural general formula as shown in the specification: R-(Xa-Nlys-Yb) n, wherein R is H, a drug active molecule or a group containing a signal marker, and X and Y are independently selected from any one of glycine residues and imidic acid residues; nlys is a residue of N-(4-aminobutyl) glycine; a and b are independently selected from any integer between 0 and 3; n is any positive integer from 3 to 10. The compound can target a glycosaminoglycan chain in cartilage through electrostatic interaction, has an effect of resisting protease degradation, and is beneficial to prolonging the in-vivo circulation time. The compound supports systemic administration, can be used for marking whole body cartilage through intravenous injection, is used for monitoring cartilage development, aging and pathological changes in real time, and has wide application potential in the aspects of molecular imaging, drug delivery and biological materials for treating cartilage-related diseases.

The invention belongs to the field of biosensing and biological interface engineering, and particularly relates to a double-enhanced bionic glycopeptide electrochemical biosensor based on anti-pollution and anti-enzymolysis stability and a preparation method of the double-enhanced bionic glycopeptide electrochemical biosensor. The invention is inspired by glycoprotein in vascular endothelial cell glycocalyx, a novel glycopeptide material capable of enhancing biological pollution resistance and protease hydrolysis resistance stability is constructed by performing glycosylation modification at the C terminal of a polypeptide sequence, and the novel glycopeptide material is applied to a complex biological medium and has remarkable performance superior to that of non-glycosylated peptide.

The invention relates to the field of microbiology, in particular to lactobacillus plantarum A3 and application thereof. The lactobacillus plantarum is named as lactobacillus plantarum A3, the preservation number is CCTCC (China Center for Type Culture Collection) NO: M 2026320, and the preservation unit is China Center for Type Culture Collection. According to the invention, a safe lactobacillus plantarum A3 is successfully separated and obtained, and a novel bacteriocin Plantaricin A3 is identified from the safe lactobacillus plantarum A3; the bacteriocin Plantaricin A3 has excellent thermal stability, pH stability and protease hydrolysis resistance, is wide in antibacterial spectrum, particularly has a remarkable effect on aquatic pathogenic vibrio, and has a wide application prospect in the fields of food, feed and aquaculture.

The invention discloses a preparation method of high-stability superoxide dismutase (SOD), and belongs to the technical field of bioengineering and enzyme engineering. The method comprises the following steps: chemically modifying purified SOD (superoxide dismutase) under the conditions of low temperature and neutral pH (potential of hydrogen) by taking monomethoxy polyethylene glycol succinimido active ester as a modifier; carrying out ultrafiltration preliminary purification on the reaction liquid, then carrying out deep purification through ion exchange chromatography, and separating to obtain a high-purity modified product; and finally, sterilizing, filtering and freeze-drying to obtain the freeze-dried powder. According to the method, by optimizing a modification and purification process, the thermal stability and protease degradation resistance of SOD are remarkably improved, and meanwhile, most enzyme activity of SOD is effectively reserved. The prepared PEG-SOD product is high in purity and good in stability, and is suitable for preparing anti-inflammatory, anti-oxidation or anti-aging medicines and functional foods.

The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of α1-antitrypsin deficiency (A1AD or AATD).

The present application relates to a kind of D / L amino acid alternate arrangement anti-hair loss hair growth peptide and its preparation method and application, belong to biological medicine technical field.The amino acid sequence of the polypeptide is as shown in SEQ ID NO:1, is designed by D type and L type amino acid alternate arrangement, significantly enhance the ability of anti-protease degradation, in vitro half-life is ≥48 hours, and activate β-catenin protein expression in hair follicle stem cell.Its preparation method includes: using Rink Amide resin as carrier, using Fmoc solid-phase synthesis method sequentially coupling D / L type amino acid, after cleaving resin by trifluoroacetic acid, by high performance liquid chromatography purification, yield is ≥80%, purity is ≥96%, mass spectrum confirms molecular weight is 956.12Da.The polypeptide can be applied to the preparation of anti-hair loss hair growth cosmetics, drugs and medical devices, effectively solve the problem of low polypeptide stability, insufficient targeting in prior art.

The invention discloses a compound preparation for regulating vaginal microecology as well as preparation and application thereof, and relates to the field of biological medicines. The composite preparation is composed of a fusion polypeptide and a monoclonal antibody according to the ratio of 1: 2 (w / w), the fusion polypeptide comprises a cell adhesion domain, an enzymolysis linking peptide and a quorum sensing inhibition domain, the amino acid sequence is shown as SEQ ID NO: 1, and the protease hydrolysis resistance is improved by more than 4 times after cyclization oxidation; the monoclonal antibody takes specific surface protein of lactobacillus inertus as a target spot, and can induce the strain to generate H2O2 phenotype conversion. An in-vitro experiment shows that the degradation rate of the composite preparation on a vaginal bacterial biofilm reaches 92.3 + / -2.4%, the ratio of lactobacillus acidophilus is remarkably increased to 63.8 + / -3.3%, and the pH is effectively adjusted to 4.3; animal experiments show that compared with commercially available metronidazole gel, the compound preparation can more remarkably promote proliferation of lactobacillus, inhibit escherichia coli and staphylococcus aureus and restore vaginal micro-ecological balance, and a new scheme is provided for treatment of vaginal micro-ecological imbalance related diseases.

The present invention relates to recombinant proteins having an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins and the use thereof. Furthermore, the present invention relates to fusion proteins comprising an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins combined with a fusion partner and optionally a linker region. Also, novel protease resistant Fc-fragments are disclosed herein.

The invention relates to the technical field of immunodetection, and discloses an immunochromatography reagent for detecting an antiproteinase 3 antibody and application, which are used for detecting the antiproteinase 3 antibody in human serum, plasma or whole blood and assisting in diagnosing wegener granuloma. The sample pad is used for bearing a to-be-detected sample; the combination pad is coated with an anti-human immune globulin antibody or an anti-human IgG antibody marked by a marker; the detection line is coated with a recombinant protease 3 antigen, myeloperoxidase antigen fragments related to Wegner granuloma attack are added, and hydrophilic polysaccharides are adopted as spacer arms to be arranged at intervals; the quality control line is coated with a goat anti-mouse IgG antibody; the water absorption pad is used for absorbing liquid in the chromatography process and promoting the liquid to flow unidirectionally; the bottom plate is used for bearing all the components, and all the components are sequentially and mutually assembled on the bottom plate to form a detection test strip; the immunochromatography reagent is extremely simple and convenient to operate, professional laboratory equipment and complex operation skills are not needed, and a detection result can be obtained only by dropwise adding a sample onto the test strip.

The application discloses an enzyme mutant with improved thermal stability and a gene and application thereof, and relates to the technical fields of genetic engineering and enzyme engineering. The application provides a mannanase mutant Man74s, and an amino acid sequence of the mannanase mutant Man74s is shown as SEQ ID NO:2. The mannanase mutant Man74s has high thermal stability, and has high activity in an acidic and neutral range at normal temperature, and other characteristics such as resistance to protease degradation, the optimal pH value of the mannanase mutant Man74s is 6.0, the mannanase mutant Man74s has relatively high catalytic activity in the pH range of 5.0-7.0, the optimal temperature is 50 DEG C, the residual enzyme activity of the mannanase Man74s is still above 70% after being treated at 85 DEG C for 3 min, and the mannanase Man74s is suitable for a rumen animal environment such as a cow or a sheep.

The invention discloses an enzyme mutant with improved thermal stability and a gene and application thereof, and relates to the technical field of gene engineering and enzyme engineering. The invention provides a mannase mutant Man74s, wherein the amino acid sequence of the mannase mutant Man74s is as shown in SEQ ID NO: 2. The mannase mutant Man74s disclosed by the invention has high thermal stability and has the characteristics of high activity, protease degradation resistance and the like in acidic and neutral ranges at normal temperature, the optimal pH value of the mannase mutant Man74s is 6.0, and the mannase mutant Man74s has relatively high catalytic activity in a pH range of 5.0-7.0; the optimal temperature is 50 DEG C, the residual enzyme activity is still 70% or above after mannase Man74s is treated at 85 DEG C for 3 min, and the mannase Man74s is suitable for rumen animal environments such as cattle and sheep.

The invention belongs to the field of medicines, and particularly relates to a CD71-targeting ROS responsive micelle as well as a preparation method and application thereof. In order to improve the efficacy of an anti-tumor drug in treating AML patients and reduce toxic and side effects, the invention provides a nano drug delivery system, namely a CD71-targeted ROS responsive micelle, which comprises the following components: amphiphilic molecules with ROS response, DSPE-PEG-DT7 and an anti-tumor drug. The micelle provided by the invention adopts a small molecule polypeptide ligand, so that competition with endogenous Tf is avoided, the micelle has protease digestion resistance, and the targeting property in blood and the in-vivo stability are improved; an amphiphilic block containing ROS responsiveness is introduced as a micelle skeleton, so that specific drug release in AML cells is realized, the curative effect is enhanced, and the side effect is reduced; aiming at AML (acute myelogenous leukemia) cells with ROS (reactive oxygen species) rise caused by FLT3-ITD mutation, the micelle disclosed by the invention can be used for effectively releasing drugs and generating a stronger drug effect reaction.

The crosslinked peptidomimetic macrocycles disclosed herein comprise an alkene or alkyne staple and a poly-amino acid C-terminal tail. These crosslinked peptidomimetic macrocycles have improved binding to MDM2 and MDMX (aka MDM4), are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.

The invention provides application of phosvitin in preparation of a medicine for treating inflammatory bowel diseases. The inflammatory bowel disease comprises ulcerative colitis, and the ulcerative colitis is colitis induced by DSS (Di-Sulfate Sodium Sulfate). The phosvitin is natural protein extracted from eggs and has no adverse reaction on human bodies, and discomfort caused by long-term anti-inflammatory drug treatment is avoided. The phosvitin provided by the invention has the property of high net negative charge, so that the phosvitin has an anti-proteolysis effect, can resist a stomach high-acid environment, reaches intestinal tracts and exerts a curative effect.

The invention discloses an anti-protease K monoclonal antibody and application thereof. A heavy chain variable region of the antibody comprises the following complementarity determining regions: VH-CDR1 as shown in SEQ NO.2, VH-CDR2 as shown in SEQ NO.4 and VH-CDR3 as shown in SEQ NO.6; the light chain variable region comprises the following complementarity determining regions: VL-CDR1 as shown in SEQ NO.9, VL-CDR2 as shown in SEQ NO.11 and VL-CDR3 as shown in SEQ NO.13, and the VH-CDR1-3 and the VL-CDR1-3 jointly form a protease K binding site. The anti-proteinase K monoclonal antibody can be applied to various nucleic acid detection technologies such as PCR, qPCR and reverse transcription PCR, the use process is simple, the anti-proteinase K monoclonal antibody is directly added to a reaction system, the activity of the proteinase K can be effectively inhibited without a pretreatment step, the active site of the proteinase K can be accurately targeted through the specific inhibition effect, the activity of the proteinase K can be specifically blocked, and meanwhile, the application range of the anti-proteinase K monoclonal antibody is widened. The activity of common nucleic acid polymerase (Taq, reverse transcriptase and the like) is not obviously influenced, complete neutralization can be realized at a low dosage, and excellent high efficiency is shown.

The present invention relates to lipid compounds that can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and / or analogues thereof, and / or polymer conjugated lipids to form lipid nanoparticles for delivery of therapeutic and / or prophylactic agents. In some examples, lipid nanoparticles are used to deliver nucleic acids, such as messenger RNA and / or antisense RNA. Methods of using these lipid nanoparticles to treat and / or prevent various diseases are also provided.In one embodiment, a compound having the structure of formula (I) below is provided:or a salt or isomer thereof or an N-oxide thereof, wherein RI is as defined herein.Pharmaceutical compositions comprising one or more compounds of the aforementioned structural formula (I) and therapeutic and / or prophylactic agents are also provided. In some embodiments, the pharmaceutical composition further comprises one or more components selected from neutral lipids, charged lipids, steroids, and polymer conjugated lipids. These compositions are useful for forming lipid nanoparticles to deliver therapeutic and / or prophylactic agents.In other embodiments, the invention provides a method of administering a therapeutic agent and / or prophylactic agent to a subject in need thereof, the method is that pharmaceutical composition comprising lipid nanoparticles and a therapeutic agent and / or prophylactic agent with a compound of formula (I) was prepared, and delivering the composition to the subject.

The present invention relates to a novel method for determining the activity of a protein ligase based on bioluminescence, which is generally applicable to various protein ligases, can be used for the characterization, activity tracking and inhibitor screening of known protein ligases, and can also be used for screening various novel protein ligases from plants and other sources. The present invention is characterized in that the recognition sequence of the protein ligase is fused to the C-terminal of the inactive NanoLuc luciferase large fragment (LgBiT) by recombinant expression or other methods, and the nucleophilic attack sequence recognized by the protein ligase is introduced at the N-terminal of the low-affinity SmBiT complementary tag by chemical synthesis or other methods. The activity determination method is based on bioluminescence detection, and has the advantages of high sensitivity, simple operation, anti-protease interference, and suitability for high-throughput screening, and plays an important role in studying known protein ligases or screening unknown protein ligases.

The invention belongs to the field of biological medicines, and relates to a pharmaceutical composition of a protease drug and an immunomodulator for treating phenylketonuria, which has the technical scheme that the protease drug and the immunomodulator for treating phenylketonuria are combined, so that the generation of an anti-protease drug antibody can be effectively reduced, and the curative effect is improved. The in-vivo action time of the protease medicine is prolonged. The invention has the beneficial effects that the combined drug can effectively reduce the immunogenicity of the protease drug, reduce the generation of in-vivo drug antibodies, prolong the action time of the drug, reduce the administration frequency of the protease drug, greatly improve the compliance of patients with phenylketonuria, and reduce the cost. Therefore, the combined medicine can be widely applied to treatment of phenylketonuria.

The present invention relates to the fields of genetic engineering and enzyme engineering. Provided are an enzyme mutant with improved thermostability, a gene thereof and the use thereof. Provided is a β-mannanase mutant. Compared with an amino acid sequence as shown in SEQ ID NO: 2, the β-mannanase mutant contains at least one of the following mutations: V86Y, A248P, and H317N. The β- mannanase mutant has an optimum pH of 6.0, has a relatively good enzymatic activity, pH stability and thermostability at pH 3.5-7.0, and has a relatively good protease resistance. The β-mannanase mutant has broad application prospects in food, feed, papermaking and textiles.

The invention discloses a preparation method of a novel BimBH3 mimic peptide analogue modified by glycosylation and fatty acid acylation double sites and application of the BimBH3 mimic peptide analogue as a PTPN1 inhibitor long-acting hypoglycemic drug. The structural general formula of the BimBH3 mimic peptide analogue is as shown in formula I: # imgabs0 # mimic peptide compound is derived from a core region of a BimBH3 structural domain, Fmoc-Lys (Dde)-OH is adopted to replace and modify the second site of a peptide chain, palmitic acid or octadecanedioic acid is adopted to perform conjugation modification on the N end of the peptide chain, sialic acid, galactosyl diacid and fructosyl acid are adopted to perform conjugation modification on the amino group on the side chain of 2-site lysine, and the BimBH3 mimic peptide analogue is obtained through conjugation modification on the amino group on the side chain of 2-site lysine. The glycosylated / fatty acid double-site decoration modified BimBH3 mimic peptide has excellent inhibitory activity on PTPN1, the problem of poor water solubility caused by fatty acylation modification can be remarkably improved after hydrophilic glycosyl is introduced into a molecular structure, and the solubility in an aqueous solution is remarkably improved. The PTPN1 inhibitor has excellent anti-protease and plasma degradation biological stability, is long in half-life period, is a potential long-acting PTPN1 inhibitor, and can be applied to the development of medicines for treating related diseases such as diabetes, cancer, obesity and the like by taking PTPN1 as a target spot.

Protease nexin-1 (PN-1) is a member of the serine protease inhibitor (Serpin)-family, with thrombin as its main target. Current polyclonal and monoclonal antibodies against PN-1 frequently cross-react with Plasminogen activator inhibitor-1 (PAI-1), a structurally and functionally homologous Serpin. Herein the inventors develop inhibitory single-domain antibodies (VHHs) showing specific binding to both human (hPN-1) and murine (mPN-1) PN-1 and which de not cross-react with PAI-1. Importantly, all VHHs could block PN-1 activity in plasma as well as PN-1 released from activated platelets, one of the main sources of PN-1 during hemostasis. Thus, the present invention relates to anti-protease nexin-1 (PN-1) conformational single domain antibodies and uses thereof in particular in the therapeutic field for the treatment of haemorrhagic diseases.

The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as α1-antitrypsin deficiency (A1AD or AATD).

A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).

The invention relates to the technical field of albendazole treatment, and particularly discloses a pharmaceutical composition for treating albendazole, 2-8 parts of nefenavir, 30-50 parts of polylactic acid-glycolic acid copolymer (PLGA), 5-15 parts of chitosan, 3-8 parts of sodium cholate and 1-3 parts of vitamin E succinate. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 5-15 parts of albendazole, 2-8 parts of nefenavir, 30-50 parts of polylactic acid-glycolic acid copolymer (PLGA), 5-15 parts of chitosan, 3-8 parts of sodium cholate and 1-3 parts of vitamin E succinate. 20 to 35 parts of lactose and 0.5 to 2 parts of magnesium stearate. The albendazole can inhibit synthesis of polypide microtubulin, the nefenavir is an anti-HIV protease inhibitor and can assist the albendazole to penetrate through the cyst wall of echinococcal, penetrability is enhanced through drug combination, the problem that the albendazole is limited in curative effect and depends on host immunity is solved, the albendazole and sodium cholate form a eutectic crystal, and the albendazole-sodium cholate co-crystal is used for preparing the albendazole-sodium cholate co-crystal. The dissolution behavior is effectively improved; in addition, as an antioxidant, vitamin E succinate can reduce oxidative degradation of albendazole in an acid environment, and the vitamin E succinate and the PLGA-chitosan slow release system cooperate to guarantee the drug stability.